EnteroMedics Inc. : EnteroMedics to Present at Seventh Annual JMP Securities Healthcare Conference
07/09/2012| 08:05am US/Eastern
Recommend:
ST. PAUL, MN -- (Marketwire) -- 07/09/12 -- EnteroMedics Inc.
(NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity, metabolic diseases
and other gastrointestinal disorders, today announced that
Greg S. Lea, SVP and Chief Financial Officer, is scheduled to
present at the 7th Annual JMP Securities Healthcare
Conference on Friday, July 13, 2012 at 1:30 pm Eastern Time,
at the Peninsula Hotel, New York, NY. Mr. Lea will provide an
overview of the Company and an update on its VBLOC® vagal
blocking therapy development and commercialization program.
The presentation will be webcast live and may be accessed by
visiting EnteroMedics' website at www.enteromedics.com. A
replay of the webcast will also be available immediately
after the conclusion of the presentation for a period of
thirty days. Investors can access the webcast under
"Press Room" in the "Investors" section
of EnteroMedics' website.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
EnteroMedics' proprietary technology, VBLOC® vagal
blocking therapy, delivered by a pacemaker-like device called
the Maestro® Rechargeable System, is designed to
intermittently block the vagus nerves using high-frequency,
low-energy, electrical impulses. VBLOC allows people with
obesity to take a positive path towards weight loss,
addressing the lifelong challenge of obesity and its
comorbidities without sacrificing wellbeing or comfort.
EnteroMedics has received CE Mark and is listed on the
Australian Register of Therapeutic Goods.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about
EnteroMedics Inc. Our actual results could differ materially
from those discussed due to known and unknown risks,
uncertainties and other factors including our limited history
of operations; our losses since inception and for the
foreseeable future; our lack of commercial regulatory
approval for our Maestro® System for the treatment of obesity
in the United States or in any foreign market other than
Australia and the European Community; our preliminary
findings from our EMPOWER™ pivotal trial; our ability to
comply with the Nasdaq continued listing requirements; our
ability to commercialize our Maestro System; our dependence
on third parties to initiate and perform our clinical trials;
the need to obtain regulatory approval for any modifications
to our Maestro System; physician adoption of our Maestro
System and VBLOC® vagal blocking therapy; our ability to
obtain third party coding, coverage or payment levels;
ongoing regulatory compliance; our dependence on third party
manufacturers and suppliers; the successful development of
our sales and marketing capabilities; our ability to raise
additional capital when needed; international
commercialization and operation; our ability to attract and
retain management and other personnel and to manage our
growth effectively; potential product liability claims;
potential healthcare fraud and abuse claims; healthcare
legislative reform; and our ability to obtain and maintain
intellectual property protection for our technology and
products. These and additional risks and uncertainties are
described more fully in the Company's filings with the
Securities and Exchange Commission, particularly those
factors identified as "risk factors" in the annual
report on Form 10-K filed March 15, 2012. We are providing
this information as of the date of this press release and do
not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
Caution -- Investigational device. Limited by Federal (United
States) law to investigational use. EnteroMedics has received
CE Mark and is listed on the Australian Register of
Therapeutic Goods.
The implantation procedure and usage of the Maestro® System
carry some risks, such as the risks generally associated with
laparoscopic procedures and those related to treatment as
described in the ReCharge clinical trial informed consent.
Contact:
EnteroMedics Inc.
Greg S. Lea
(651) 789-2860
Email Contact
Source: EnteroMedics
News Provided by Acquire Media
distributed by
|
|
Recommend :
